Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	17.78B
Revenue (ttm)	4.52B
Net Income (ttm)	254.63M
Shares Out	531.96M
EPS (ttm)	0.45
PE Ratio	74.81
Forward PE	25.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	527,496
Average Volume	604,753
Open	33.00
Previous Close	33.42
Day's Range	32.90 - 33.70
52-Week Range	31.45 - 47.30
Beta	1.53
RSI	32.02
Earnings Date	Jul 18, 2025

About Despegar.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.